SEC INSIDER TRANSACTIONS

INCYTE CORP (INCY) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

INCY · INCYTE CORP

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 53 filings · fetched 2026-11-13T18:19:43Z

Recent reported activity

0purchase rows on this page

11sale rows on this page

194matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,293D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,642D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,623D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	3,023D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,643D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,864D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,623D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	9,459D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F6	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,072D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F5	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	3,148D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F4	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,709D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F3	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,284D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References: F2	M Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,918D	0	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	2,293D	119.41	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	326D	121.69	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	85D	122.19	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	1,642D	119.38	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	1,643D	119.51	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	2,864D	119.4	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	4,695D	119.39	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	6,171D	119.43	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	2,187D	119.47	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	5,332D	119.42	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	S Sale (market/private)Common Stock · Non-derivative	14,661D	119.46	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	326A	105.43	Direct	Form 4 ↗0002079962-26-000013

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.